- Iproniazid
- Iproniazid dihydrochloride
- Iproniazid phosphate
- 54923-31-82(1H)-Pyridinone,5-bromo-6-methyl-
- 549-23-56H-2-Benzopyran-6,8(7H)-dione,7-(acetyloxy)-5-chloro-3-[(1E,3E,5S)-3,5-dimethyl-1,3-heptadien-1-yl]-7-methyl-,(7R)-
- 54924-33-34-Piperidinemethanol, a-(4-fluorophenyl)-
- 54925-64-31H-Imidazole,1-[(1,1-dimethylethyl)dimethylsilyl]-
- 54927-63-82H-Pyran-2-acetic acid,6-[[(2R,3R,4R,5S,7S,9R,10R)-3,9-dimethoxy-2,4,10-trimethyl-2-[(2S,2'R,5R,5'R)-octahydro-5'-[(2S,3S,5R,6S)-tetrahydro-6-hydroxy-3,5,6-trimethyl-2H-pyran-2-yl][2,2'-bifuran]-5-yl]-1,6-dioxaspiro[4.5]dec-7-yl]methyl]tetrahydro-2-hydroxy-4-methoxy-a,3,5-trimethyl-5-[[(2S,5S,6R)-tetrahydro-5-methoxy-6-methyl-2H-pyran-2-yl]oxy]-,(aR,2S,3S,4S,5S,6S)-
- 54930-39-13-(4-methylphenyl)propan-1-amine
- 54932-72-8Benzene,4-bromo-1-chloro-2-methyl-
- 54932-90-04(15),10(14)-Muuroladiene
- 5493-45-81,2-Cyclohexanedicarboxylicacid, 1,2-bis(2-oxiranylmethyl) ester
- 54939-58-1Benzenamine,2-(difluoromethoxy)-5-nitro-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Iproniazid |
EINECS | N/A |
| CAS No. | 54-92-2 | Density | 1.1305 (rough estimate) |
| PSA | 54.02000 | LogP | 1.50620 |
| Solubility | N/A | Melting Point |
112.5-113.5° |
| Formula | C9H13 N3 O | Boiling Point | 311.75°C (rough estimate) |
| Molecular Weight | 179.222 | Flash Point | N/A |
| Transport Information | N/A | Appearance | N/A |
| Safety | A human poison by ingestion. An experimental poison by ingestion, intraperitoneal, and intravenous routes. Moderately toxic by skin contact, intramuscular, and subcutaneous routes. Human systemic effects by ingestion: constipation, anuria, metabolic changes, change in liver function. Human reproductive effects by ingestion: impotence. Experimental reproductive effects. Mutation data reported. Questionable carcinogen with experimental tumorigenic and teratogenic data. Used as an antidepressant. When heated to decomposition it emits toxic fumes of NOx. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Isonicotinicacid, 2-isopropylhydrazide (6CI,8CI); 1-Isonicotinoyl-2-isopropylhydrazine;Euphozid; IPN; Iprazid; Iprazide; Iproniazid; Iproniazide; Isonicotinic acidN'-isopropyl hydrazide; Marsalid; Marsilid; N'-Isopropylisonicotinoylhydrazide |
Article Data | 7 |
Iproniazid Chemical Properties
Product Name: Iproniazid
CAS Registry Number: 54-92-2
IUPAC Name: N'-propan-2-ylpyridine-4-carbohydrazide
Molecular Weight: 179.21902 [g/mol]
Molecular Formula: C9H13N3O
XLogP3: 0.4
H-Bond Donor: 2
H-Bond Acceptor: 3
EINECS: 200-218-8
Surface Tension: 41.5 dyne/cm
Density: 1.084 g/cm3
Flash Point: 114.6 °C
Enthalpy of Vaporization: 50.39 kJ/mol
Boiling Point: 265.9 °C at 760 mmHg
Vapour Pressure: 0.00891 mmHg at 25°C
Following is the molecular structure of Iproniazid (CAS NO.54-92-2) is:
Iproniazid History
Iproniazid was the first antidepressant ever marketed. It was originally intended for the treatment of tuberculosis. Its antidepressant properties were discovered when researchers noted that the patients given iproniazid became "inappropriately happy" in 1952, . It was subsequently developed as an antidepressant and was approved for use in 1958. It was later withdrawn in 1961 due to the unacceptable incidence of hepatitis and was replaced by less hepatotoxic drugs like isocarboxazid (Marplan), phenelzine (Nardil), and tranylcypromine (Parnate).
Iproniazid Uses
Iproniazid (CAS NO.54-92-2) is an irreversible inhibitor of monoamine oxidase types A and B that is used as an antidepressive agent. It has also been used as an antitubercular agent, but its use is limited by its toxicity.
Iproniazid Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | oral | 95mg/kg (95mg/kg) | Annals of the New York Academy of Sciences. Vol. 80, Pg. 626, 1959. | |
| human | TDLo | oral | 2143ug/kg/D (2.143mg/kg) | GASTROINTESTINAL: DECREASED MOTILITY OR CONSTIPATION KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED | Acta Neurologia et Psychiatrica Belgica. Vol. 59, Pg. 977, 1959. |
| monkey | LD50 | oral | 640mg/kg (640mg/kg) | Annals of the New York Academy of Sciences. Vol. 80, Pg. 626, 1959. | |
| mouse | LD50 | intramuscular | 615mg/kg (615mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | American Review of Tuberculosis. Vol. 65, Pg. 376, 1952. |
| mouse | LD50 | intraperitoneal | 475mg/kg (475mg/kg) | BEHAVIORAL: ANTICONVULSANT | Japanese Journal of Pharmacology. Vol. 13, Pg. 186, 1963. |
| mouse | LD50 | intravenous | 719mg/kg (719mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | American Review of Tuberculosis. Vol. 65, Pg. 376, 1952. |
| mouse | LD50 | oral | 440mg/kg (440mg/kg) | Pharmaceutical Chemistry Journal Vol. 30, Pg. 750, 1996. | |
| mouse | LD50 | subcutaneous | 730mg/kg (730mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | American Review of Tuberculosis. Vol. 65, Pg. 376, 1952. |
| rabbit | LD50 | intravenous | 117mg/kg (117mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | American Review of Tuberculosis. Vol. 65, Pg. 376, 1952. |
| rabbit | LD50 | oral | 125mg/kg (125mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | American Review of Tuberculosis. Vol. 65, Pg. 376, 1952. |
| rabbit | LDLo | skin | 2gm/kg (2000mg/kg) | Huntingdon Research Center Reports. Vol. -, Pg. -, 1972. | |
| rat | LD50 | intraperitoneal | 375mg/kg (375mg/kg) | BEHAVIORAL: ANTICONVULSANT | Japanese Journal of Pharmacology. Vol. 13, Pg. 186, 1963. |
| rat | LD50 | oral | 365mg/kg (365mg/kg) | BEHAVIORAL: TOXIC PSYCHOSIS | Nature. Vol. 185, Pg. 532, 1960. |
| rat | LD50 | subcutaneous | 538mg/kg (538mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 119, Pg. 444, 1957. | |
| rat | LD50 | unreported | 350mg/kg (350mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 363, 1970. | |
| women | LDLo | oral | 14mg/kg/2W-I (14mg/kg) | LIVER: OTHER CHANGES | Canadian Medical Association Journal. Vol. 78, Pg. 131, 1958. |
Iproniazid Safety Profile
A human poison by ingestion. An experimental poison by ingestion, intraperitoneal, and intravenous routes. Moderately toxic by skin contact, intramuscular, and subcutaneous routes. Human systemic effects by ingestion: constipation, anuria, metabolic changes, change in liver function. Human reproductive effects by ingestion: impotence. Experimental reproductive effects. Mutation data reported. Questionable carcinogen with experimental tumorigenic and teratogenic data. Used as an antidepressant. When heated to decomposition it emits toxic fumes of NOx.
Iproniazid Specification
Iproniazid , its cas register number is 54-92-2. It also can be called Iproniazid [USAN:INN:BAN] ; 1-Isonicotinoyl-2-isopropylhydrazine ; 4-22-00-00551 (Beilstein Handbook Reference) ; BRN 0142700 ; CCRIS 9177 ; EINECS 200-218-8 ; Euphozid ; IPN ; Iprazid ; Iproniazid ; Iproniazida ; Iproniazida [INN-Spanish] ; Iproniazide ; Iproniazide [INN-French] ; Iproniazidum ; Iproniazidum [INN-Latin] ; Iproniazyd ; Iproniazyd [Polish] ; Isonicotinic acid, N'-isopropyl hydrazide ; Marsalid ; Marsilid ; N'-Isopropylisonicotinoylhydrazide ; P 887 ; Rivivol ; Ro 2-4572 ; UNII-D892HFI3XA ; Yatrozide ; 4-Pyridinecarboxylic acid, 2-(1-methylethyl)hydrazide Iproniazid ; Isonicotinic acid 2-isopropylhydrazide .
Iproniazid (CAS NO.54-92-2) acts as an irreversible and nonselective monoamine oxidase inhibitor (MAOI). Also, it is still used in France.
What can I do for you?
Get Best Price
